- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.07. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 23.07. | Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH | 226 | GlobeNewswire (Europe) | WILMINGTON, Del., July 23, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary... ► Artikel lesen | |
| 14.07. | Inhibikase sells $50M of common stock to RA Capital | 1 | Seeking Alpha | ||
| 14.07. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.07. | Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility | 209 | GlobeNewswire (Europe) | WILMINGTON, Del., July 14, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary... ► Artikel lesen | |
| INHIBIKASE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 02.07. | Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 29.06. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 19.05. | Cantor Fitzgerald reiterates Inhibikase stock Overweight rating at $4 | 3 | Investing.com | ||
| 12.05. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.05. | Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity | 228 | GlobeNewswire (Europe) | WILMINGTON, Del., May 12, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary... ► Artikel lesen | |
| 08.04. | H.C. Wainwright reiterates Inhibikase stock rating on trial progress | 2 | Investing.com | ||
| 07.04. | Inhibikase: Erster Patient in Phase-3-Studie für Lungenhochdruck-Medikament aufgenommen | 3 | Investing.com Deutsch | ||
| 07.04. | Inhibikase startet Phase-3-Studie für Lungenhochdruck-Medikament mit erstem Patienten | 6 | Investing.com Deutsch | ||
| 07.04. | Inhibikase enrolls first patient in Phase 3 PAH drug trial | 1 | Investing.com | ||
| 07.04. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.04. | Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 26.03. | Inhibikase Therapeutics GAAP EPS of -$0.49 | 1 | Seeking Alpha | ||
| 26.03. | Inhibikase Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 26.03. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 26.03. | Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity | 467 | GlobeNewswire (Europe) | WILMINGTON, Del., March 26, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify... ► Artikel lesen |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABBVIE | 223,40 | -3,00 % | AbbVie vor möglichem Ausbruch? Pharmawerte mit relativer Stärke | Nach dem Sprung über die 200-Tage-Linie setzte AbbVie den Aufwärtstrend fort und korrigierte zuletzt bis an die 20-Tage-Linie. Dort stabilisierte sich der Kurs, während die jüngsten Hochs das kurzfristige... ► Artikel lesen | |
| TEVA | 30,700 | +0,99 % | Medincell: UZEDY: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook | Regulatory News:
Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY U.S. net sales reached a record $77 million in Q2 2026, up 43%... ► Artikel lesen | |
| EYEPOINT | 11,100 | +5,71 % | EyePoint, Inc.: EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU for Treatment of Diabetic Macular Edema (DME) | - COMO and CAPRI trials together rapidly enrolled over 480 participants in five months, demonstrating continued enthusiasm for DURAVYU trial participation among retinal specialists and patients --... ► Artikel lesen | |
| ORGANIGRAM GLOBAL | 0,797 | -1,48 % | Organigram Global Inc.: Organigram Closes Previously Announced Acquisition of Sanity Group, Private Placement Financing with BAT and ATB Senior Secured Credit Facilities | Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram") and Sanity Group GmbH ("Sanity" or "Sanity Group") jointly announced the successful closing of Organigram's previously... ► Artikel lesen | |
| QUANTUM BIOPHARMA | 2,494 | +1,46 % | Quantum BioPharma Announces Closing of Debt Settlement | THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, July 30, 2026... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 61,96 | +3,40 % | Does Nektar (NKTR) Have the Potential to Rally 104.06% as Wall Street Analysts Expect? | ||
| AMARIN | 12,000 | -3,23 % | Amarin Corporation plc: Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence | Q2 2026 Results Highlight Global Volume Growth, Lower Operating Expenses and Positive Cash Flow For Full Year 2026, Company Expects Continued Growth in International Markets, Maintenance of VASCEPA's... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 219,80 | -1,70 % | Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth | ||
| SELLAS LIFE SCIENCES | 8,820 | +0,23 % | SELLAS Life Sciences Group, Inc. - 8-K, Current Report | ||
| MADRIGAL PHARMACEUTICALS | 420,80 | -11,76 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates | Second-quarter 2026 Rezdiffra- (resmetirom) net sales of $364.3 million, representing year-over-year growth of 71% As of June 30, 2026, more than 49,000 patients on Rezdiffra, more than doubling... ► Artikel lesen | |
| XORTX THERAPEUTICS | 1,829 | +2,38 % | XORTX Therapeutics Inc.: XORTX Appoints New Director | CALGARY, Alberta, July 29, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 70,91 | -2,85 % | AKTIONÄR-Tipp BridgeBio nach 212 % Plus - geht die Rally weiter? | Die Aktie von BridgeBio Pharma hat sich seit der Empfehlung des AKTIONÄR im November 2024 extrem stark entwickelt. Gut 212 Prozent liegt das Papier seitdem im Plus - ein glatter Verdreifacher. Und zuletzt... ► Artikel lesen | |
| OPUS GENETICS | 3,320 | +9,21 % | Opus Genetics stock coverage initiated at TD Cowen on gene therapy | ||
| RIGEL PHARMACEUTICALS | 32,850 | -1,65 % | Rigel Pharmaceuticals, Inc.: Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer | Dr. Hannah has decades of oncology drug development experience and has served on Rigel's Board of Directors since 2021
She has resigned from Rigel's Board of... ► Artikel lesen | |
| SAVARA | 4,966 | +7,98 % | Savara Inc.: Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041 | -- In December 2025, Savara and PARI Were Granted a Joint European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI, Delivered Via PARI's Proprietary eFlow Nebulizer System... ► Artikel lesen |
Das Unternehmen INHIBIKASE THERAPEUTICS INC kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell -1,08 % bei einem Aktienkurs von 2,285 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INHIBIKASE THERAPEUTICS INC finden Sie auf Wallstreet Online.